These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 22230300)
1. Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship. Kotsianidis I; Spanoudakis E; Nakou E; Miltiades P; Margaritis D; Tsatalas C; Tzouvelekis A; Oikonomou A Leuk Res; 2012 Apr; 36(4):e90-2. PubMed ID: 22230300 [No Abstract] [Full Text] [Related]
2. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics. Turturro F; Leary C; Stephens J; Veillon D; Lowery-Nordberg M J Clin Oncol; 2010 Aug; 28(22):e380-1. PubMed ID: 20458054 [No Abstract] [Full Text] [Related]
3. Acute myeloblastic leukemia. Molina CA; Rodríguez MJ; de Marcos NS; Font P Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629 [TBL] [Abstract][Full Text] [Related]
4. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature. Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466 [No Abstract] [Full Text] [Related]
5. Is there an association between 5-azacitidine and ototoxicity? Malik A; Misbah S; Spaccavento C; Yudelman I J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015 [No Abstract] [Full Text] [Related]
6. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924 [TBL] [Abstract][Full Text] [Related]
7. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone. Almeida AM; Pierdomenico F Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173 [No Abstract] [Full Text] [Related]
8. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. Feldmann G; Brossart P; von Lilienfeld-Toal M Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506 [No Abstract] [Full Text] [Related]
9. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome. Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928 [No Abstract] [Full Text] [Related]
10. Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine. Lai SW; Huang TC; Ye RH; Wu YY Eur J Haematol; 2015 Mar; 94(3):273-6. PubMed ID: 24797511 [TBL] [Abstract][Full Text] [Related]
11. Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report. Goo K; Uy R; Roswarski J J Oncol Pharm Pract; 2019 Jul; 25(5):1248-1252. PubMed ID: 29933727 [TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease associated with azacitidine use: a case report. Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671 [TBL] [Abstract][Full Text] [Related]
13. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Haas PS; Wijermans P; Verhoef G; Lübbert M Leuk Res; 2006 Mar; 30(3):338-42. PubMed ID: 16162357 [TBL] [Abstract][Full Text] [Related]
15. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068 [No Abstract] [Full Text] [Related]
16. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan. Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559 [TBL] [Abstract][Full Text] [Related]
17. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome. Makita S; Munakata W; Watabe D; Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Fukuhara S; Maruyama D; Kobayashi Y; Tobinai K J Int Med Res; 2017 Apr; 45(2):886-893. PubMed ID: 28415946 [TBL] [Abstract][Full Text] [Related]
18. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. Hueser CN; Patel AJ Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893 [TBL] [Abstract][Full Text] [Related]
19. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient. Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907 [No Abstract] [Full Text] [Related]
20. Azacitidine adverse effects in patients with myelodysplastic syndromes. San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]